Medexus Pharmaceuticals (MDP) Competitors C$2.15 +0.04 (+1.90%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades MDP vs. LEAF, CRDL, RX, HLS, TGOD, NINE, WMD, SUGR, VIR, and ZOMShould you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Leaf Mobile (LEAF), Cardiol Therapeutics (CRDL), BioSyent (RX), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), SugarBud Craft Growers (SUGR), Viridium Pacific Group (VIR), and Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM). These companies are all part of the "drug manufacturers - specialty & generic" industry. Medexus Pharmaceuticals vs. Leaf Mobile Cardiol Therapeutics BioSyent HLS Therapeutics Green Organic Dutchman Delta 9 Cannabis WeedMD SugarBud Craft Growers Viridium Pacific Group Zomedica Pharmaceuticals Corp. (ZOM.V) Leaf Mobile (TSE:LEAF) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Does the MarketBeat Community favor LEAF or MDP? Leaf Mobile received 165 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Medexus Pharmaceuticals an outperform vote while only 65.89% of users gave Leaf Mobile an outperform vote. CompanyUnderperformOutperformLeaf MobileOutperform Votes17065.89% Underperform Votes8834.11% Medexus PharmaceuticalsOutperform Votes5100.00% Underperform VotesNo Votes Which has stronger valuation and earnings, LEAF or MDP? Leaf Mobile has higher earnings, but lower revenue than Medexus Pharmaceuticals. Leaf Mobile is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeaf MobileC$83.74M0.00C$3.37MC$0.04N/AMedexus PharmaceuticalsC$108.78M0.48C$1.09MC$0.0543.00 Do analysts rate LEAF or MDP? Medexus Pharmaceuticals has a consensus price target of C$5.25, suggesting a potential upside of 144.19%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Leaf Mobile.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leaf Mobile 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Does the media refer more to LEAF or MDP? In the previous week, Medexus Pharmaceuticals had 3 more articles in the media than Leaf Mobile. MarketBeat recorded 3 mentions for Medexus Pharmaceuticals and 0 mentions for Leaf Mobile. Leaf Mobile's average media sentiment score of 0.00 beat Medexus Pharmaceuticals' score of -0.20 indicating that Leaf Mobile is being referred to more favorably in the media. Company Overall Sentiment Leaf Mobile Neutral Medexus Pharmaceuticals Neutral Do institutionals and insiders believe in LEAF or MDP? 8.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is LEAF or MDP more profitable? Medexus Pharmaceuticals has a net margin of 1.00% compared to Leaf Mobile's net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 3.95% beat Leaf Mobile's return on equity.Company Net Margins Return on Equity Return on Assets Leaf MobileN/A N/A N/A Medexus Pharmaceuticals 1.00%3.95%4.89% SummaryMedexus Pharmaceuticals beats Leaf Mobile on 13 of the 17 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDP vs. The Competition Export to ExcelMetricMedexus PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$52.74MC$1.17BC$5.05BC$6.25BDividend YieldN/A3.13%4.97%5.27%P/E Ratio43.00110.0297.3426.84Price / Sales0.482,171.601,218.421,531.29Price / CashN/A10.4333.5183.81Price / Book1.623.135.803.15Net IncomeC$1.09MC$159.31MC$119.07MC$299.38M7 Day Performance5.91%-1.08%-1.83%0.76%1 Month Performance-14.00%-3.82%-3.64%12.82%1 Year Performance41.45%87.63%31.62%44.03% Medexus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDPMedexus Pharmaceuticals2.8807 of 5 starsC$2.15+1.9%C$5.25+144.2%+36.9%C$52.74MC$108.78M43.0098Analyst UpgradeLEAFLeaf MobileN/AN/AN/AN/AC$198.42MC$83.74M58.86150CRDLCardiol TherapeuticsN/AC$2.18-4.8%N/A+80.2%C$152.34MN/A-4.9520RXBioSyentN/AC$11.30+3.6%N/A+36.1%C$130.97MC$33.82M18.83N/ANews CoverageHigh Trading VolumeHLSHLS Therapeutics1.3206 of 5 starsC$3.13-2.5%C$3.63+15.8%-14.9%C$99.50MC$58.89M-3.1091High Trading VolumeTGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940Gap UpWMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap UpSUGRSugarBud Craft GrowersN/AC$9.00-2.7%N/A+8,081.8%C$61.38MC$575.64M10.8444Gap DownVIRViridium Pacific GroupN/AC$0.38+5.6%N/A+0.0%C$37.52MC$1.09M-2.97580Positive NewsGap UpZOMZomedica Pharmaceuticals Corp. (ZOM.V)N/AC$0.29-6.6%N/A+0.0%C$36.73MN/A-2.6150Gap Down Related Companies and Tools Related Companies Leaf Mobile Competitors Cardiol Therapeutics Competitors BioSyent Competitors HLS Therapeutics Competitors Green Organic Dutchman Competitors Delta 9 Cannabis Competitors WeedMD Competitors SugarBud Craft Growers Competitors Viridium Pacific Group Competitors Zomedica Pharmaceuticals Corp. (ZOM.V) Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:MDP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
